News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Email Alerts Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go Advanced Search Keywords Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Oct 25, 2005 Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance Oct 25, 2005 FDA to Review Insmed's Complete Response to Approvable Letter for iPlex Oct 24, 2005 Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference Oct 18, 2005 Insmed to Present at the BIO Investor Forum Conference Oct 17, 2005 Insmed Submits Response to FDA Approvable Letter for iPlex Sep 29, 2005 Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release Sep 29, 2005 Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency Sep 25, 2005 Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST Sep 24, 2005 Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director Sep 19, 2005 SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France Aug 8, 2005 Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005 Aug 2, 2005 Insmed to Release Second Quarter Financial Results; Monday, August 8 Jun 10, 2005 FDA Extends PDUFA Date for SomatoKine to October 03, 2005 May 31, 2005 Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome May 25, 2005 Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005 May 24, 2005 Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica May 19, 2005 Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005 May 17, 2005 Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer May 10, 2005 Insmed Incorporated Reports Financial Results for First Quarter of 2005 May 5, 2005 Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET) Apr 26, 2005 Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance Apr 20, 2005 Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R) Apr 18, 2005 Patent Infringement Suit Against Insmed Dismissed Apr 13, 2005 FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome Mar 16, 2005 Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004 Show 5102550100 per page«1…202122232425262728» Stay In The Loop Want to stay up to date on our news, events, and filings? Set up your email alerts. Sign Up View the latest Insmed Investor Presentation Download